Value Bridge — NEWARK BETH ISRAEL MEDICAL CENTER
Current $-61M → Target $-46M (+$14.8M)
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
$-61.1M
Current EBITDA
$-46.3M
Target EBITDA
+$14.8M
Total Uplift
7
Value Levers
EBITDA Bridge — 7 Lever Model
Each lever shows gross impact, probability of achievement, and probability-weighted value.
Denial Rate Reduction
$0.0M
AR Acceleration
$0.0M
Coding Accuracy Uplift
$3.3M
Payer Mix Optimization
$8.0M
Cost to Collect Reduction
$2.7M
Clean Claim Improvement
$2.0M
Volume & Rate Growth
$13.4M
What This Means
The 7-lever model projects a 0% EBITDA uplift from $-61M to $-46M. The highest-impact lever is Volume & Rate Growth at $5.4M probability-weighted.
IC talking point: "We see $15M in annual EBITDA improvement, primarily from volume & rate growth. At an 11x multiple, this represents $163M in equity value creation."